Newer Blood Thinners Cut Stroke Risk in Intermediate-Risk AFib Patients

The randomized SINGLE-AF trial, presented at ESC Congress 2026 and published in the New England Journal of Medicine, found that direct oral anticoagulants (DOACs) reduced serious clinical events by 69% in atrial fibrillation patients with an intermediate stroke risk. The primary benefit was a decrease in ischemic strokes, with no increase in major bleeding. These findings provide strong evidence supporting DOAC use in this patient group, potentially influencing future treatment guidelines.